Welcome to our dedicated page for Kazia Therapeuti SEC filings (Ticker: KZIA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kazia Therapeutics Limited (NASDAQ: KZIA) files as a foreign private issuer with the U.S. Securities and Exchange Commission, primarily using Form 20-F for annual reporting and Form 6-K for current reports. This SEC filings page for KZIA brings together those regulatory documents and pairs them with AI-generated summaries to help readers interpret the company’s disclosures.
For a clinical-stage oncology company like Kazia, Form 6-K reports often incorporate press releases and transaction details by reference. Recent 6-K filings describe private placements of equity securities, the terms of pre-funded warrants and American Depositary Shares, at-the-market offering agreements, and collaboration and in-licensing arrangements such as the PD-L1 protein degrader program with QIMR Berghofer. Other 6-Ks discuss Nasdaq listing notices, the company’s responses, and subsequent steps taken to regain or demonstrate compliance with listing standards.
These filings also reference how capital raised is intended to support the continued clinical development of Kazia’s lead programs, including paxalisib, a brain-penetrant PI3K / Akt / mTOR pathway inhibitor, and EVT801, a VEGFR3 inhibitor, as well as the PD-L1 degrader program. Supplemental risk factor disclosures in certain filings provide additional detail on regulatory approval processes, combination therapy development, and ongoing regulatory obligations after any potential approvals.
On this page, AI-powered tools can help explain the structure and implications of Kazia’s 6-K filings, highlight key terms in financing agreements, and summarize how new collaborations or regulatory updates relate to the company’s oncology pipeline. Users can also review references to incorporated press releases, understand how offerings may affect capital structure, and see how Kazia describes its strategy for maintaining Nasdaq listing and advancing its investigational cancer therapies.
Kazia Therapeutics Ltd: This Schedule 13G/A discloses that Alumni Capital LP, Alumni Capital GP LLC and Ashkan Mapar are collectively reported as beneficially owning 178,591 American Depository Shares (ADSs), representing 9.99% of the class on the filing’s stated basis. The reported percentage is calculated using the issuer's representation of 1,609,108 ADSs outstanding and reflects an Ownership Limitation that prevents the Fund from acquiring ADSs that would raise ownership above 9.99%.
The filing clarifies that the Fund actually owns 28,409 ADSs as of the filing date but may be deemed to beneficially own additional ADSs pursuant to a Purchase Agreement (dated April 19, 2024), Commitment Warrants, Common Warrants (dated January 10, 2025) and a July 31, 2025 Securities Purchase Agreement. All three Reporting Persons share voting and dispositive power over the 178,591 ADSs. Signatures are dated 09/11/2025.
Kazia Therapeutics Limited submitted a Form 6-K to provide investors with a new press release about its cancer drug candidate paxalisib. The release, dated September 11, 2025, is titled “Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy.” The filing makes this press release publicly available as Exhibit 99.1 and incorporates its information, other than a quote from the Chief Executive Officer, into Kazia’s existing Form F-3 registration statement, which may be used for future securities offerings.
Kazia Therapeutics Ltd filed a Form D reporting a Regulation D, Rule 506(b) offering that raised $2,050,013, with $2,050,013 sold and $0 remaining. The filing lists four investors and identifies offered securities as equity, options/warrants, and securities issuable on exercise.
The notice discloses pre-funded warrants to purchase up to 204,547 ADSs, each ADS representing 500 ordinary shares, and each pre-funded warrant exercisable for one ADS at an exercise price of $0.0001 per ADS. The filing reports $0 in sales commissions and finders' fees, $0 of proceeds paid to named officers or directors, and was signed by CEO John Friend on 2025-08-14.
On 31 Jul 2025 Kazia Therapeutics (KZIA) entered a definitive agreement for a private placement expected to close on or about 4 Aug 2025. Investors will buy 14,204,500 ordinary shares at US$0.0176 per share and pre-funded warrants exercisable for up to 204,547 ADSs (1 ADS = 500 shares) at US$8.7999 per warrant, with a token exercise price of US$0.0001 per ADS. Warrant holders are limited to 9.99 % beneficial ownership unless they give 61-day notice to increase the cap.
The transaction should yield ~US$2 million net proceeds after expenses. Kazia intends to direct the funds toward ongoing clinical development of paxalisib (brain-penetrant PI3K/mTOR inhibitor) and EVT801 (VEGFR3 inhibitor) and for general corporate purposes. The securities were issued under Section 4(a)(2) and Rule 506 exemptions; Kazia must file a resale registration statement within 60 days of closing and keep it effective until investors no longer hold the securities.
No financial results or guidance were provided. Closing remains subject to customary conditions.